Well Informed. Utilization Program Updates to Promote Guideline Adherence. Effective January 1, 2018:
|
|
- Peregrine Cain
- 5 years ago
- Views:
Transcription
1 Q As we continue our rapid growth under the ownership of The Carlyle Group, we have a lot of exciting news to share. This edition details upcoming changes to our 2018 drug utilization programs and explores the merits of allowing transitional retail pharmacy fills. We also announce a recent award bestowed upon US Specialty Care; provide links to our H2 pipeline reports; and include a list of new FDA-approved drugs. We hope this information is beneficial and reflects our ongoing commitment to both our clients and plan participants. Please let us know if you have any questions or if there is anything we can do to strengthen our relationship. Sincerely, Zach Johnson, President, WellDyneRx Well Informed Effective January 1, 2018: Utilization Program Updates to Promote Guideline Adherence Beginning January 1, 2018, WellDyneRx will require prior authorizations (PAs) and/or quantity level limits (QLLs) for the following medications. These programs were developed in collaboration with an external pharmacy and therapeutics (P&T) committee to ensure prescribing practices are consistent with evidence and guidelines. The QLLs are based on safety and efficacy testing results. Quantities above the recommended limit are allowed on a case-by-case basis when evidence supports the use of higher doses. Actinic Keratosis (AK) Actinic keratosis, or sun spots, are rough, scaly or crusty growths on the skin that develop from years of exposure to the sun. There are numerous topical products on the market to treat AK, including four categories of topical medications: topical 5-fluorouracil (5-FU), topical imiquimod, topical ingenol mebutate, and topical diclofenac. The products within each of these categories are a mix of generic and brand name medications. The brand products vary in cost from $200 to $3000 for a one month supply. Clinical guidelines recommend using generic topical 5-FU or imiquimod, since these treatments are less expensive and range in price from between $75 and $300 for a one month supply. Prior authorizations will be required for approved indications and/or trial and failure of a less expensive medication, or the same medication(s) in a non-combination form. There are many treatment alternatives available for each of the drugs noted. Amrix Amrix is an extended-release formulation of Flexeril (cyclobenzaprine) which is indicated for the treatment of muscle spasms associated with acute painful musculoskeletal conditions. Amrix costs between $1200 and $2300 for a one month (Continues on next page) Q Well Informed
2 (Continued from previous page) supply, while a 90 day supply of cyclobenzaprine (at the highest dose) costs only $100. Cambia Cambia is a powder for oral solution formulation of diclofenac potassium and it is indicated for migraine attacks. Although Cambia is a nonsteroidal anti-inflammatory (NSAID) drug similar to ibuprofen, it costs $68 per packet while ibuprofen is available overthe-counter (OTC), and as a prescription, for about $20 a month. Diclofenac also comes in a tablet formulation and costs approximately $30 a month. Clinical guidelines show that ibuprofen, at standard doses, is effective for acute migraine treatment. Jublia and Kerydin Jublia and Kerydin are both topical formulations used to treat onychomycosis (toenail fungus). Jublia costs between $700 and $1,400 and must be applied daily for 48 weeks, yielding only a 15% cure rate. Kerydin costs between $700 and $1,700 and also must be applied daily for 48 weeks, yielding only a 9.1% cure rate. Clinical guidelines recommend the use of oral antifungals as first-line therapy, with topical formulations being reserved for the last line of treatment. Tetracyclines Tetracyclines are a class of medications commonly used to treat bacterial infections, including both bacterial-derived acne and inflammationderived acne. Despite being used successfully for many years, newer acne treatment options are available, but they do not necessarily improve safety or efficacy. These newer brand name products range in price from $1 to $35 per capsule. WellDyneRx recommends introducing additional controls on these products as existing, less expensive, therapies are equally effective. These programs are expected to cause minimal patient disruption while providing significant cost savings for your plan. While these policies do not go into effect until January 1, 2018, WellDyneRx clients may adopt them sooner. For more information, contact your Account Executive. Lidocaine Lidocaine 5% ointment is a topical anesthetic indicated for intubation, venipuncture, and minor skin discomfort and irritation. It costs between $200 and $1500 for a 100 gram tube and off-label utilization is common. For minor topical skin discomforts, WelldyneRx recommends that plan participants try OTC products before using Lidocaine ointment, and then only for FDAapproved indications. Q Well Informed 2
3 US SPECIALTY CARE WINS Specialty Pharmacy PATIENT CHOICE AWARDS US Specialty Care (USSC) was named the winner of the Specialty Pharmacy Patient Choice Awards (PBM/Payer Specialty Pharmacy category) during the 2017 Asembia Specialty Pharmacy Summit. The Patient Choice Award recognizes specialty pharmacies with the highest patient satisfaction ratings across the United States. John Monahan, CEO of Zitter Health Insights (ZHI) and co-sponsor of the event, said the award honors specialty pharmacies that deliver the highest levels of patient satisfaction in a complex and challenging industry that demands expert care for seriously ill patients. By providing a consistent level of care, concern and commitment for overall patient health and well-being, these U.S. specialty pharmacies are taking their profession to new heights. Specialty Medications: Transitional Retail Fills are Unnecessary When new clients engage with US Specialty Care (USSC), they often wonder whether or not they should allow their plan participants to fill initial prescriptions for specialty medications at retail pharmacies. They believe that adopting this grace period will enable their members to get their specialty medication(s) quickly, without having to wait for USSC prescription delivery shipments to arrive USSC was selected based on results from the ZHI 2016 Patient Satisfaction Survey, which is representative of 80 percent of specialty pharmacies across the United States. The other finalists in the PBM/Payer Specialty Pharmacy category were CVS Health and Humana Specialty Pharmacy. USSC ultimately won the award based on overall patient satisfaction scores. For more detailed information about the award, please read the press release. We are very proud of this achievement as it demonstrates our commitment to providing quality member care while containing our client s costs. in the mail. While this practice may offer some benefits for clients transitioning to mandatory prescription delivery service for traditional medications, it may actually delay treatment for members taking specialty medications. Nearly all specialty medications require prior authorizations (PAs), and there is usually a delay in therapy associated with fulfilling the PA requirements, irrespective of where the prescription is filled. Secondly, due to the high cost of most specialty medications, many retail pharmacies don t keep them in stock and only order (Continues on next page) Q Well Informed 3
4 (Continued from previous page) them for patients when they receive a paid claim. Due to these factors, initiation of therapy is usually delayed regardless of whether the prescription is filled at a retail or specialty pharmacy. Additionally, transitioning patients to a specialty pharmacy after the first fill can cause delays and gaps in treatment if the member does not fully appreciate that they must get subsequent prescriptions filled exclusively through USSC. Finally, allowing members to fill prescriptions for specialty medications at retail pharmacies often increases costs for our clients as these pharmacies may not receive the same contracted rates as USSC and the staff at these pharmacies are not as well versed in the financial solutions (copay cards, etc.) available for specialty medications. WellDyneRx recommends against allowing transitional retail fills for specialty medications. This plan design option does not translate well to specialty medications and ultimately puts the member at a higher risk for treatment gaps. Q Well Informed 4
5 H Drug Pipeline REPORTS NOW AVAILABLE Please click the links below to access drug pipeline reports for the second half of 2017: Biosimilar Drug Pipeline Report Brand Drug Pipeline Report Generic Drug Pipeline Report Specialty Drug Pipeline Report These publications include: Descriptions of newly approved drugs, including product highlights, place in therapy, and market impact Summaries of specialty, nonspecialty, biosimilar, and generic drugs with anticipated FDA approval dates in the upcoming 12 months Additional FDA actions, including rejections and indications for specific drugs If you have any questions, please contact your account management team. UPCOMING Conferences Tradeshows Representatives from WellDyneRx will be attending the following conferences in the near future. If you are attending any of these events and would like to schedule an onsite meeting, please let us know. TABA 2017 Fall Conference & Membership Meeting September 26-27, 2017 The Woodlands, TX (Attending Only - Not Exhibiting) AmeriBen s 49th Annual Leadership Conference September 27-29, 2017 Sun Valley, ID (Booth #TBD) SIIA 37th Annual National Education Conference October 8-10, 2017 Phoenix, AZ (Booth #300) IFEBP 63rd Annual Employee Benefits Conference October 22-25, 2017 Las Vegas, NV (Booth #204) & Q Well Informed 5
6 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Zerviate (Nicox Ophthalmics Inc.) cetirizine ophthalmic solution Allergies Zerviate is a histamine-1 receptor antagonist ophthalmic solution indicated for treatment of ocular itching associated with allergic conjunctivitis. It is available as 2.4 mg cetirizine in 1 ml sterile solution. The recommended dose is one drop in each affected eye twice daily. Kevzara (Sanofi Synthelabo) sarilumab Rheumatoid Arthritis Kevzara solution is an interleukin-6 receptor antagonist indicated for adults with moderateto-severe active rheumatoid arthritis (RA) with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). It contains a black box warning for severe infection and it is available in 150 mg/1.14 ml or 200 mg/1.14 ml pre-filled syringes. The recommended dose is 200 mg once every 2 weeks subcutaneous (SQ). Radicava (Mitsubishi Tanabe Pharma) edaravone Amyotrophic Lateral Sclerosis Radicava is indicated for amyotrophic lateral sclerosis (ALS). It is available as a 30 mg/100 ml single dose for injection. The initial recommended dose is 60 mg intravenous (IV) daily for 14 days, followed by a 14 day drug free period. Subsequent cycles are 60 mg daily for 10 out of 14 days, followed by a 14 day drug free period. Kisqali Femara Co-Pack (Novartis Pharms Corp.) ribociclib; letrozole Breast Cancer Kisqali Femara Co-Pack is indicated for postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced, or metastatic breast cancer. It is available as 200 mg Kisqali and 2.5 mg Femara. Kisqali is dosed 600 mg daily for 21 days, followed by 7 days off. Femara is dosed 2.5 mg daily for 28 days. Q Well Informed 6
7 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Imfinzi (Astrazeneca) durvalumab Urothelial Carcinoma Imfinzi is a programmed death ligand-1 (PD-L1) blocking antibody indicated for locally advanced or metastatic urothelial carcinoma that has progressed during or following platinum containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. It is available as 500 mg/10 ml or 120 mg/2.4 ml vials for injection and is dosed at 10 mg/ kg IV every 2 weeks. Alunbrig (Ariad) brigatinib Non-Small Cell Lung Cancer Alunbrig is a kinase inhibitor indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed or are intolerant to crizotinib. It is available as a 30 mg or 90 mg tablet. The recommended dose is 90 mg once daily for 7 days, then increase to 180 mg once daily. Tymlos (Radius Health Inc.) abaloparatide Osteoporosis Tymlos is a human parathyroid hormone-related peptide analog indicated for postmenopausal women with osteoporosis at high risk for fracture. It is available as a 3120 mcg/1.56 ml prefilled syringe. The recommended dose is 80 mcg SQ once daily. Low Rydapt (Novartis Pharms Corp.) midostaurin Acute Myeloid Leukemia Rydapt is a kinase inhibitor indicated for adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive in combination with cytarabine and daunorubicin induction and cytarabine consolidation. It is available as a 25 mg capsule and is dosed at 50 mg twice daily. Q Well Informed 7
8 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Brineura (Biomarin Pharm) cerliponase alfa Tripeptidyl Peptidase 1 Deficiency Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated for patients 3 years of age or older to slow the loss of ambulation in symptomatic patients with tripeptidyl peptidase 1 deficiency. It is available as a 150 mg/5 ml IV injection. The recommended dose is 300 mg once every other week. Xatmep (Silvergate Pharma, Inc.) methotrexate Juvenile idiopathic arthritis and acute lymphoid leukemia Xatmep is an oral solution of methotrexate indicated for management of active polyarticular juvenile idiopathic (pjia) arthritis and pediatric acute lymphoid leukemia (ALL). The recommended dose is 10 mg/m2 once weekly for pjia and 20 mg/ m2 once weekly for ALL. Renflexis (Samsung Bioepsis CO.) infliximab-abda Multiple immunologic disorders Renflexis is a biosimilar to Remicade used to treat Crohn s disease in adults and pediatrics; ulcerative colitis, RA, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It is an antibody which neutralizes tumor necrosis factor alpha (TNFα). The dose is 5 mg/kg IV at 0, 2 and 6 weeks, then every 8 weeks. High RoxyBond (Inspirion Delivery Sciences, LLC) oxycodone hydrochloride Pain RoxyBond is an abuse-deterrent opioid agonist indicated to treat pain that is severe enough to require opioid analgesics and for which alternative treatments are inadequate. It is available in 5 mg, 15 mg, and 30 mg tablets. The recommended dose is 5 mg to 15 mg every 4 to 6 hours as needed for pain. Low Q Well Informed 8
9 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Ingrezza (Neurocrine) valbenazine tosylate Tardive dyskinesia Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated to treat tardive dyskinesia in adults. It is taken as a 40 mg capsule once daily for one week and then increased to 80 mg once daily as tolerated. Austedo (Teva) deutetrabenazine Huntington s Disease Austedo is a VMAT2 inhibitor indicated for the treatment of chorea associated with Huntington s disease. The dose is 6 mg tablet once daily and titrated at 6 mg per week if tolerated. Dupixent (Regeneron Pharmaceuticals) dupilumab Atopic dermatitis Dupixent is an interleukin-4 receptor alpha antagonist for patients with moderate-to-severe atopic dermatitis. The initial dose is 600 mg SQ, then 300 mg SQ every other week. Low Ocrevus (Genetech Inc.) ocrelizumab Multiple sclerosis Ocrevus is a CD-20 antibody indicated for adult patients with relapsing or primary progressive forms of multiple sclerosis. The initial dose is 300 mg IV followed two weeks later by a second 300 mg IV. Subsequent doses are 600 mg IV every 6 months. Zejula (Tesaro Inc.) niraparib tosylate Ovarian, fallopian tube, or primary peritoneal cancer Zejula is indicated for ovarian, fallopian tube, or primary peritoneal cancer to cause DNA damage, apoptosis, and cell death. It is a 300 mg capsule taken once daily. Q Well Informed 9
10 NEW FDA-APPROVED DRUGS BRAND NAME GENERIC NAME(S) THERAPEUTIC USE BRIEF DESCRIPTION POTENTIAL IMPACT Bavencio (EMD Serono Inc.) avelumab Metastatic Merkel cell carcinoma and urothelial carcinoma Bavencio is a PD-L1 blocking antibody indicated for adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. Bavencio is available as a 200 mg/10 ml solution single-dose vial. The recommended dose is 10 mg/ kg IV every 2 weeks. Symproic (Shionogi) naldemdine tosylate Opioid-induced constipation Symproic is an opioid antagonist used to treat opioid-induced constipation and chronic noncancer pain. It is a 0.2 mg tablet taken once daily. Xadago (US Worldmeds) safinamide mesylate Parkinson s Disease Xadago is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson s disease experiencing off episodes. It is a MAO type B inhibitor and works to increase dopamine in the brain. The recommended dose is 50 mg once daily, then titrated to 100 mg after 2 weeks based on tolerability. Low Kisqali (Novartis Pharmarceutical Corporation) ribociclib Breast cancer Kisqali tablets are indicated for postmenopausal women with HR+, HER2- advanced or metastatic breast cancer. It is available as 200 mg tabs and the recommended dose is 600 mg orally once daily for 21 days. Feedback, Questions or Suggestions. Please contact us at wellinformed@welldynerx.com. Thank you! Q Well Informed 10
Added, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE THIRD QUARTER 2017 NEW DRUG ARRIVALS SUMMARY TABLE. Utilization Management Recommendation
RT 1,2, 3,5 Drug Name 1 Brigatinib (Alunbrig ) 1 Deutetrabenazine (Austedo ) 1 Cerliponase alfa (Brineura ) Review Reason FDA-Approved (s) Alunbrig is indicated patients with anaplastic lymphoma kinase
More informationNew Drugs of ,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication
1 New Drugs of 2017 1,3,5,7,10,14,16,20,22,24,26,28,30,32,34,36,38,40,41,43,45-86 Brand Name/ Generic Name/ Approved Indication Company Aliqopa Copanlisib Dihydrochloride Intravenous Bayer HealthCare Pharmaceuticals
More informationLUNCH AND LEARN. May 11, CE Activity Information & Accreditation
LUNCH AND LEARN May 11, 2018 Featured Speaker: Mary Lynn Moody, B.S. Pharm. Assistant Dean for Business Development Clinical Associate Professor Drug Information and Prior Authorization Group Department
More informationClinical Overview of Innovative New Drug Approvals in 2017
Reddy: Clinical Overview of Innovative New Drug Approvals in 2017 4225 International Journal of Pharmaceutical Sciences and Nanotechnology Review Article Clinical Overview of Innovative New Drug Approvals
More informationOral Oncology Agents. August 2017 Update. SGLT-2 Category Update. Removal of Medical Foods
SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE SEPTEMBER 2017 ISSUE 4 HELPFUL NUMBERS FOR PROVIDERS CVS: 1-888-512-8935 Primary: 004336 Secondary Commercial: 013089 Secondary
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationNew Exception Status Benefits
AUGUST 2018 Nova Scotia Formulary Updates New Exception Status Benefits Ibrance (palbociclib) Erelzi (etanercept) Criteria Updates Ciprodex (dexamethasone and ciprofloxacin) Duloxetine (Cymbalta and generic
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationCYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID
CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID BACKGROUND Cytokine and cell-adhesion molecule (CAM) antagonists have a major role in the treatment of chronic inflammatory diseases such
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationKentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and November 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
More informationWell Informed. WellManaged - Diabetes INTRODUCING: WellDyneRx plan participants are eligible to receive a free One Touch System glucose meter
Q4 2 0 1 7 Well Informed With 2017 winding down, we re taking stock of how we performed throughout the year and setting goals for 2018. Towards that end, we recently distributed our annual Client Satisfaction
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationBehind the scenes at Green Shield Canada s preferred pharmacy network
SPRING 2018 Behind the scenes at Green Shield Canada s preferred pharmacy network Remember the preferred pharmacy network (PPN)? Let s refresh your memory: Green Shield Canada (GSC) introduced the PPN
More informationNew Product to Market: Lucemyra Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the November 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationXATMEP (methotrexate) oral solution
XATMEP (methotrexate) oral solution Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationNB Drug Plans Formulary Update
Bulletin # 965 January 22, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective January 22, 2018. Included in this bulletin: Special Authorization Benefit
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: November 30, 2018 Xenazine Description Xenazine (tetrabenazine)
More informationSpecialty drugs are a significant cost trend driver for
2009 Drug Utilization and Cost Trends: Tumor Necrosis Factor Inhibitors Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; and John A. Szychowski, AAS, BS Specialty drugs are a significant
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationRegulatory Status FDA-approved indication: Otrexup and Rasuvo are folate analog metabolic inhibitors indicated for: (1-2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.37 Subject: Methotrexate Injections Page: 1 of 5 Last Review Date: March 16, 2018 Methotrexate Injections
More informationBENEFIT CHANGES TO NBPDP
Bulletin #789 June 15, 2010 BENEFIT CHANGES TO NBPDP This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 15, 2010. Included in this bulletin: Regular Benefit
More informationSpecialty Pharmacy Pipeline
Specialty Pharmacy Pipeline Drugs to Watch Anticipated Launches Q1 Q2 2017 Atopic Dermatitis Dupixent (dupilumab) Subcutaneous injection Regeneron Pharmaceuticals/Sanofi moderate-to-severe atopic dermatitis
More informationAnticipated Launches Q Q1 2019
Anticipated Launches Q4 2018-Q1 2019 Disease Prevalence Amyloidosis Tegsedi (inotersen) subcutaneous (SC) injection Akcea s/ionis Pharmaceuticals hereditary transthyretin amyloidosis (hattr) with polyneuropathy,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationAustedo. Austedo (deutetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.15 Subject: Austedo Page: 1 of 6 Last Review Date: September 15, 2017 Austedo Description Austedo
More informationWell Informed. A Comprehensive Approach to Pain Management. Pain Guardian
Q1 2 0 1 7 Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Austedo TM GENERIC NAME Deutetrabenazine MANUFACTURER Teva Pharmaceuticals USA, Inc. DATE OF APPROVAL August 30, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationDecision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
9 September 2015 Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) The PHARMAC Board has approved the proposal relating to the funding of the TNF-inhibitor
More informationErelzi (etanercept) Frequently Asked Questions
Erelzi (etanercept) Frequently Asked Questions 1. What is the funding status of Erelzi (etanercept)? Effective December 21, 2017, Erelzi (etanercept) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationPublication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationNEW DRUG UPDATE. Financial Disclosures. FDA Approvals. Objectives. Withdrawals. Mark S. Johnson, Pharm.D., BCPS
Financial Disclosures NEW DRUG UPDATE Mark S. Johnson, Pharm.D., BCPS Name of commercial interest(s) Stockholder in Merck and various mutual funds Mark S. Johnson, Pharm.D., BCPS Professor of Pharmacy
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationNB Drug Plans Formulary Update
Bulletin # 967 February 12, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective February 12, 2018. Included in this bulletin: Regular Benefit Additions
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationCelecoxib Powder, Diclofenac Powder, Flurbiprofen Powder, Ibuprofen Powder, Ketoprofen Powder, Meloxicam Powder, Tramadol Powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.26 Subject: Anti-Inflammatory Pain Powders Page: 1 of 5 Last Review Date: December 3, 2015 Anti-Inflammatory
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationFDA Approval LIST. WellINFORMED
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationOrencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2018 Bulletin #169 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: benztropine mesylate, tablet,
More informationDrug Therapy Guidelines
Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review
More informationJOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.12 Subject: Xenazine Page: 1 of 5 Last Review Date: December 8, 2017 Xenazine Description Xenazine
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationCover story. Austedo Ingrezza Brineura Alunbrig Rydapt Tymlos Imfinzi Radicava Kevzara Baxdela Bevyxxa
Cover story Downloaded via 148.251.232.83 on March 9, 2019 at 14:34:33 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. Trulance Parsabiv Emflaza
More informationMedication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
More informationProposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
14 July 2015 Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines
More informationCircle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Humira (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationInfliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)
Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More information1.5 PHARMACOLOGY CREDITS
1.5 ANCC CONTACT HOURS 1.5 PHARMACOLOGY CREDITS NewD Drugs PART 2 BY DANIEL A. HUSSAR, PhD REMINGTON PROFESSOR OF PHARMACY PHILADELPHIA COLLEGE OF PHARMACY UNIVERSITY OF THE SCIENCES PHILADELPHIA, PA.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationVesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza )
Vesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza ) Applies to all products administered or underwritten by Blue Cross and
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA
ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA Now Available 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml EWING, N.J., March 29, 2016 Antares Pharma, Inc. (NASDAQ:
More information2018 Travelers Prescription Drug Plan High Deductible + HSA Plan
2018 Travelers Prescription Drug Plan High Deductible + HSA Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that section National Preferred Formulary
More information1 x weekly 50 mg. Consumption:
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)
More information2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N
12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE
More informationMifegymiso. New Exception Status Benefits
OCTOBER 2017 Nova Scotia Formulary Updates Mifegymiso New Exception Status Benefits Prozac (fluoxetine syr) Neupro (rotigotine) Brenzys (etanercept) Changes in Benefit Status Criteria Updates OAB Medications
More informationLYNPARZA (olaparib) oral capsule and tablet
LYNPARZA (olaparib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMedication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry
More informationPrior Authorization Conditions for Approval of Enbrel (etanercept) Website Form Submit request via: Fax
Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Enbrel (etanercept) require a prior
More informationSMC briefing note. The following medicines were accepted for use: The following medicine has not been recommended for use: About SMC.
Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medicines Consortium. The detailed advice for each medicine
More information2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationHow does my new treatment work?
How does my new treatment work? Get to know KEVZARA better. Click here for full Prescribing Information including 1 risk of SERIOUS SIDE EFFECTS and Medication Guide. You're starting KEVZARA... GOT A QUESTION?
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationAre Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More information